|
1
|
Lipworth L, Tarone RE and McLaughlin JK:
The epidemiology of renal cell carcinoma. J Urol. 176:2353–2358.
2006.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Eichelberg C, Junker K, Ljungberg B and
Moch H: Diagnostic and prognostic molecular markers for renal cell
carcinoma: A critical appraisal of the current state of research
and clinical applicability. Eur Urol. 55:851–863. 2009.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L,
Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014
update. Eur Urol. 67:913–924. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Landolt L, Eikrem O, Strauss P, Scherer A,
Lovett DH, Beisland C, Finne K, Osman T, Ibrahim MM, Gausdal G, et
al: Clear cell renal cell carcinoma is linked to
epithelial-to-mesenchymal transition and to fibrosis. Physiol Rep.
5(e13305)2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899.
2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Vesely MD, Kershaw MH, Schreiber RD and
Smyth MJ: Natural innate and adaptive immunity to cancer. Annu Rev
Immunol. 29:235–271. 2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Linehan WM, Vasselli J, Srinivasan R,
Walther MM, Merino M, Choyke P, Vocke C, Schmidt L, Isaacs JS,
Glenn G, et al: Genetic basis of cancer of the kidney:
Disease-specific approaches to therapy. Clin Cancer Res.
10:6282S–6289S. 2004.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Rajandram R, Yap NY, Pailoor J, Razack AH,
Ng KL, Ong TA, Morais C and Gobe GC: Tumour necrosis factor
receptor-associated factor-1 (TRAF-1) expression is increased in
renal cell carcinoma patient serum but decreased in cancer tissue
compared with normal: Potential biomarker significance. Pathology.
46:518–522. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gougos A and Letarte M: Primary structure
of endoglin, an RGD-containing glycoprotein of human endothelial
cells. J Biol Chem. 265:8361–8364. 1990.PubMed/NCBI
|
|
10
|
Bussolati B, Bruno S, Grange C, Ferrando U
and Camussi G: Identification of a tumor-initiating stem cell
population in human renal carcinomas. FASEB J. 22:3696–3705.
2008.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Saroufim A, Messai Y, Hasmim M, Rioux N,
Iacovelli R, Verhoest G, Bensalah K, Patard JJ, Albiges L, Azzarone
B, et al: Tumoral CD105 is a novel independent prognostic marker
for prognosis in clear-cell renal cell carcinoma. Br J Cancer.
110:1778–1784. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kampinga HH, Hageman J, Vos MJ, Kubota H,
Tanguay RM, Bruford EA, Cheetham ME, Chen B and Hightower LE:
Guidelines for the nomenclature of the human heat shock proteins.
Cell Stress Chaperones. 14:105–111. 2009.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lianos GD, Alexiou GA, Mangano A, Mangano
A, Rausei S, Boni L, Dionigi G and Roukos DH: The role of heat
shock proteins in cancer. Cancer Lett. 360:114–118. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhang B, Xie F, Aziz AUR, Shao S, Li W,
Deng S, Liao X and Liu B: Heat shock protein 27 phosphorylation
regulates tumor cell migration under shear stress. Biomolecules.
9(50)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
White NM, Masui O, Desouza LV, Krakovska
O, Metias S, Romaschin AD, Honey RJ, Stewart R, Pace K, Lee J, et
al: Quantitative proteomic analysis reveals potential diagnostic
markers and pathways involved in pathogenesis of renal cell
carcinoma. Oncotarget. 5:506–518. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
de Vivar Chevez AR, Finke J and Bukowski
R: The role of inflammation in kidney cancer. Adv Exp Med Biol.
816:197–234. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Fischer K, Theil G, Hoda R and Fornara P:
Serum amyloid A: A biomarker for renal cancer. Anticancer Res.
32:1801–1804. 2012.PubMed/NCBI
|
|
18
|
Hofbauer SL, Stangl KI, de Martino M,
Lucca I, Haitel A, Shariat SF and Klatte T: Pretherapeutic
gamma-glutamyltransferase is an independent prognostic factor for
patients with renal cell carcinoma. Br J Cancer. 111:1526–1531.
2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Pan G, O'Rourke K, Chinnaiyan AM, Gentz R,
Ebner R, Ni J and Dixit VM: The receptor for the cytotoxic ligand
TRAIL. Science. 276:111–113. 1997.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Macher-Goeppinger S, Aulmann S, Tagscherer
KE, Wagener N, Haferkamp A, Penzel R, Brauckhoff A, Hohenfellner M,
Sykora J, Walczak H, et al: Prognostic value of tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) and TRAIL
receptors in renal cell cancer. Clin Cancer Res. 15:650–659.
2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Toiyama D, Takaha N, Shinnoh M, Ueda T,
Kimura Y, Nakamura T, Hongo F, Mikami K, Kamoi K, Kawauchi A and
Miki T: Significance of serum tumor necrosis factor-related
apoptosis-inducing ligand as a prognostic biomarker for renal cell
carcinoma. Mol Clin Oncol. 1:69–74. 2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Frew IJ and Moch H: A clearer view of the
molecular complexity of clear cell renal cell carcinoma. Annu Rev
Pathol. 10:263–289. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kim KH, Lee HH, Yoon YE, Na JC, Kim KS and
Han WK: Prolyl hydroxylase-3 is a novel renal cell carcinoma
biomarker. Investig Clin Urol. 60:425–431. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Svastova E, Hulikova A, Rafajova M,
Zat'ovicova M, Gibadulinova A, Casini A, Cecchi A, Scozzafava A,
Supuran CT, Pastorek J and Pastoreková S: Hypoxia activates the
capacity of tumor-associated carbonic anhydrase IX to acidify
extracellular pH. FEBS Lett. 577:439–445. 2004.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Takacova M, Bartosova M, Skvarkova L,
Zatovicova M, Vidlickova I, Csaderova L, Barathova M, Breza J Jr,
Bujdak P, Pastorek J, et al: Carbonic anhydrase IX is a clinically
significant tissue and serum biomarker associated with renal cell
carcinoma. Oncol Lett. 5:191–197. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Nisman B, Yutkin V, Nechushtan H, Gofrit
ON, Peretz T, Gronowitz S and Pode D: Circulating tumor M2 pyruvate
kinase and thymidine kinase 1 are potential predictors for disease
recurrence in renal cell carcinoma after nephrectomy. Urology.
76:513.e1–6. 2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
de Martino M, Hoetzenecker K, Ankersmit
HJ, Roth GA, Haitel A, Waldert M and Klatte T: Serum 20S proteasome
is elevated in patients with renal cell carcinoma and associated
with poor prognosis. Br J Cancer. 106:904–908. 2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Huang Y, Zhang Y, Jia L, Liu C and Xu F:
Circular RNA ABCB10 promotes tumor progression and correlates with
pejorative prognosis in clear cell renal cell carcinoma. Int J Biol
Markers. 34:176–183. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Heinemann FG, Tolkach Y, Deng M, Schmidt
D, Perner S, Kristiansen G, Muller SC and Ellinger J: Serum
miR-122-5p and miR-206 expression: Non-invasive prognostic
biomarkers for renal cell carcinoma. Clin Epigenetics.
10(11)2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Di Carlo A, Terracciano D, Mariano A,
Oliva A, D'Armiento M and Macchia V: Role of cytokeratins, nuclear
matrix proteins, Lewis antigen and epidermal growth factor receptor
in human bladder tumors. Int J Oncol. 23:757–762. 2003.PubMed/NCBI
|
|
31
|
Di Carlo A: Evaluation of neutrophil
gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9
(MMP-9) and their complex MMP-9/NGAL in sera and urine of patients
with kidney tumors. Oncol Lett. 5:1677–1681. 2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Morrissey JJ and Kharasch ED: The
specificity of urinary aquaporin 1 and perilipin 2 to screen for
renal cell carcinoma. J Urol. 189:1913–1920. 2013.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kasthuri RS, Taubman MB and Mackman N:
Role of tissue factor in cancer. J Clin Oncol. 27:4834–4838.
2009.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Silva DD, Noronha JAP, Pinheiro da Costa
BE, Zandona PCE and Carvalhal GF: Serum tissue factor as a
biomarker for renal clear cell carcinoma. Int Braz J Urol.
44:38–44. 2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Stern PH, Wallace CD and Hoffman RM:
Altered methionine metabolism occurs in all members of a set of
diverse human tumor cell lines. J Cell Physiol. 119:29–34.
1984.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Mustafa A, Gupta S, Hudes GR, Egleston BL,
Uzzo RG and Kruger WD: Serum amino acid levels as a biomarker for
renal cell carcinoma. J Urol. 186:1206–1212. 2011.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Traeger L, Ellermann I, Wiethoff H, Ihbe
J, Gallitz I, Eveslage M, Moritz R, Herrmann E, Schrader AJ and
Steinbicker AU: Serum Hepcidin and GDF-15 levels as prognostic
markers in urothelial carcinoma of the upper urinary tract and
renal cell carcinoma. BMC Cancer. 19(74)2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Lavabre-Bertrand T, Henry L, Carillo S,
Guiraud I, Ouali A, Dutaud D, Aubry L, Rossi JF and Bureau JP:
Plasma proteasome level is a potential marker in patients with
solid tumors and hemopoietic malignancies. Cancer. 92:2493–2500.
2001.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Bratu OG, Cherciu AI, Bumbu A, Lupu S,
Marcu DR, Ionita-Radu F, Manea M, Furau C, Diaconu CC and Mischianu
DLD: Retroperitoneal tumours-treatment and prognosis of tumour
recurrence. Rev Chim. 70:190–194. 2019.
|
|
40
|
Marcu DR, Ionita-Radu F, Iorga LD, Manea
M, Socea B, Scarneciu I, Isvoranu G, Costache R, Diaconu CC and
Bratu OG: Vascular involvement in primary retroperitoneal tumors.
Rev Chim (Bucharest). 70:445–448. 2019.
|
|
41
|
Boda D: Cellomics as integrative omics for
cancer. Curr Proteomics. 10:237–245. 2013.
|
|
42
|
Neagu M, Constantin C, Tanase C and Boda
D: Patented biomarker panels in early detection of cancer. Recent
Patents Biomarkers. 1:10–24. 2011.
|
